Answers are grounded in this paper and cite their sources.
The drug discovery and development process encompasses the interrogation of metabolites arising from the biotransformation of drugs. Here we look at why, when and how metabolites of small-molecule drugs are synthesised from the perspective of a specialist contract research organisation, with particular attention paid to projects for which regulatory oversight is relevant during this journey. To illustrate important aspects, we look at recent case studies, trends and learnings from our experience of making and identifying metabolites over the past ten years, along with with selected examples from the literature. Teaser: The impact of drug metabolites in clinical development, regulatory obligations, and how diverse and challenging problems were solved in real-life examples.
No takes yet. Share an insight, caveat, or question.
Shanu-Wilson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: